Adicet Bio

If prula‑cel proves to deliver durable remission in severe autoimmune indications, the addressable value per patient could be high relative to chronic immunosuppression, implying strong latent pricing power. Off‑the‑shelf supply and outpatient dosing could widen access and support payer acceptance if total cost of care is reduced.

However, actual pricing latitude will depend on comparative durability versus emerging CAR‑T competitors (largely autologous) and on safety/monitoring requirements regulators impose. At present, there is no approved autoimmune CAR‑T, and data are early; thus our score reflects meaningful upside optionality rather than demonstrated pricing leverage.